Dr. Mark D. Kochenderfer, MD

Dr. Kochenderfer practices at Blue Ridge Cancer Care in Roanoke, Virginia.

Dr. Kochenderfer's NPI, 1396720454, was assigned on December 13, 2005. Dr. Kochenderfer graduated from West Virginia University School of Medicine in 1999. Dr. Kochenderfer holds Virginia license 0101244463.

Dr. Kochenderfer's primary practice is Blue Ridge Cancer Care, at 2013 S Jefferson St, Roanoke, VA 24014 in Roanoke City. The practice phone is (540) 982-0237.

Dr. Kochenderfer's primary practice is Blue Ridge Cancer Care in Roanoke, Virginia. Dr. Kochenderfer is also affiliated with Carilion Roanoke Memorial Hospital. The medical group on file is Blue Ridge Cancer Care. Dmand AI also links Dr. Kochenderfer to 3 more hospitals and 2 hospices, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kochenderfer practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kochenderfer's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kochenderfer is licensed in Virginia.

CMS data shows 81,063 Medicare services from Dr. Kochenderfer across 68 procedure codes in 2024, for 853 Medicare patients. Medicare paid $1,984,130 for them.

CMS counts 853 Medicare patients who saw Dr. Kochenderfer in 2024. The largest group is 65 to 74, with 372 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kochenderfer's median patient age at 69, with 59% women.

In 2024, Dr. Kochenderfer wrote 1,488 Medicare Part D claims for 306 patients. 73% of them were for generic drugs. CMS names the drug for 1,256 of them, across 34 drugs with 11 or more claims each, at $4,179,033 in total drug cost. In 2023, CMS named 1,024 claims across 34 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Kochenderfer for performance year 2024, reported through an alternative payment model (APM). Dr. Kochenderfer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kochenderfer as offering telehealth.

Dmand AI links 5 papers to Dr. Kochenderfer, published from 2015 to 2024. 2020 was the busiest year, with 2. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Nivolumab. Dr. Kochenderfer has published most often in Clin Genitourin Cancer. Dr. Kochenderfer's most frequent co-authors are Ian Denison Schnadig, MD, Edward R. Arrowsmith, MD and Todd Michael Bauer, MD.

Dmand AI links Dr. Kochenderfer to 7 clinical trials, 3 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Rectal Diseases and Colorectal Neoplasms.

CMS Open Payments shows 29 general payments to Dr. Kochenderfer from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 96% of the total. Merck Sharp & Dohme Corporation paid the most, $12,450.

Dr. Kochenderfer graduated from West Virginia University School of Medicine in 1999.